Antengene (6996) investor relations material

Strategic partnership and licensing agreement

• Entered a global exclusive license agreement with UCB for ATG-201, a CD19/CD3 bispecific T-cell engager for autoimmune diseases.

• Antengene receives $80 million upfront and near-term milestone payments, with potential for up to $1.2 billion in future milestones and tiered royalties.

• Antengene will conduct first-in-human phase I studies in China and Australia, with clinical trial applications planned for Q1 2026.

• UCB will assume global clinical development and commercialization responsibilities, gaining access to Antengene's manufacturing technology for ATG-201.

• The deal leverages Antengene’s AnTenGager™ platform and UCB’s global immunology expertise, providing immediate value and long-term participation in ATG-201's global success.

Platform and pipeline innovation

• The AnTenGager™ platform features proprietary CD3 sequence, bivalent target mining, and steric hindrance masking for differentiated T-cell engagers.

• Designed to address limitations of first-generation T-cell engagers, including safety and efficacy issues, and enables disease-associated antigen-gated T-cell activation.

• Platform supports both bispecific and trispecific antibody formats, with several undisclosed trispecific programs and 9 disclosed products in preclinical development.

• ATG-201 demonstrated deep, sustained B-cell depletion and lower cytokine release in preclinical models, showing superior in vivo results compared to benchmarks.

• Additional pipeline assets include ATG-106, ATG-112, ATG-110, ATG-115, ATG-021, and ATG-102, targeting various solid tumors and hematologic malignancies.

Clinical and regulatory plans

• Clinical trial applications for ATG-201 are planned in China and Australia in Q1 2026, with first-in-human phase I studies to be completed before further development is transferred to UCB.

• Antengene has secured 32 IND approvals in the US and Asia, and 10 NDA approvals in Asia Pacific markets.

• IND submissions for other pipeline candidates are planned through 2027.